|
Jun 27
|
Daré Bioscience Announces Reverse Stock Split
|
|
Jun 24
|
Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder
|
|
Apr 1
|
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript
|
|
Mar 29
|
Q4 2023 Dare Bioscience Inc Earnings Call
|
|
Mar 28
|
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
|
|
Feb 22
|
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
|
|
Dec 26
|
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
|
|
Dec 20
|
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
|
|
Dec 7
|
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause
|
|
Dec 4
|
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
|
|
Sep 6
|
Daré Bioscience to Participate in Upcoming Investor Conferences
|
|
Sep 5
|
Daré Bioscience Completes Previously Announced Equity Financing
|
|
Aug 9
|
Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings
|
|
Aug 3
|
Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
|